CD8A and neoplasm: Furthermore, elesclomol effectively remodels the tumor immune microenvironment by promoting dendritic cell maturation and CD8<sup>+</sup> T cell infiltration, demonstrating synergistic effects with immune checkpoint blockade therapies.